Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Scudla

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Casopis Lekaru Ceskych|March 25, 1998
[The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus]V Scudla, P Horák, L Faltýnek, et al.
Vnitrni Lekarstvi|July 1, 1996
[The bromodeoxyuridine index in multiple myeloma. I. Relation with selected laboratory indicators of the disease]V Scudla, M Ordeltová, J Bacovský, et al.
Vnitrni Lekarstvi|May 26, 2006
[Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma]V Scudla, M Budíková, T Pika, et al.
Casopis Lekaru Ceskych|August 1, 2009
[The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma]V Scudla, M Budíková, T Pika, et al.
Vnitrni Lekarstvi|March 1, 2011
[Contribution of whole-body magnetic resonance in the diagnostics of monoclonal gammopathy of undetermined significance, multiple myeloma, and the assessment of Durie-Salmon Plus staging system]V Scudla, M Herman, J Minarík, et al.
Neoplasma|November 25, 2003
A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myelomaV Scudla, M Ordeltova, J Bacovsky, et al.
Neoplasma|November 10, 2009
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myelomaJ Minarik, V Scudla, J Bacovsky, et al.
Clinical Rheumatology|October 20, 2001
Clinical utility of selected disease activity markers in patients with systemic lupus erythematosusP Horák, V Scudla, Z Hermanovó, et al.
Vnitrni Lekarstvi|August 5, 2010
[Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma]V Scudla, P Petrová, J Minarík, et al.
Vnitrni Lekarstvi|September 1, 1994
[Cytogenetic findings in patients with primary myelodysplastic syndrome and their prognostic significance. (Analysis of results in 65 patients)]K Indrák, M Jarosová, I Sulovská, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Casopis Lekaru Ceskych|March 25, 1998
[The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus]V Scudla, P Horák, L Faltýnek, et al.
Vnitrni Lekarstvi|July 1, 1996
[The bromodeoxyuridine index in multiple myeloma. I. Relation with selected laboratory indicators of the disease]V Scudla, M Ordeltová, J Bacovský, et al.
Vnitrni Lekarstvi|May 26, 2006
[Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma]V Scudla, M Budíková, T Pika, et al.
Casopis Lekaru Ceskych|August 1, 2009
[The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma]V Scudla, M Budíková, T Pika, et al.
Vnitrni Lekarstvi|March 1, 2011
[Contribution of whole-body magnetic resonance in the diagnostics of monoclonal gammopathy of undetermined significance, multiple myeloma, and the assessment of Durie-Salmon Plus staging system]V Scudla, M Herman, J Minarík, et al.
Neoplasma|November 25, 2003
A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myelomaV Scudla, M Ordeltova, J Bacovsky, et al.
Neoplasma|November 10, 2009
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myelomaJ Minarik, V Scudla, J Bacovsky, et al.
Clinical Rheumatology|October 20, 2001
Clinical utility of selected disease activity markers in patients with systemic lupus erythematosusP Horák, V Scudla, Z Hermanovó, et al.
Vnitrni Lekarstvi|August 5, 2010
[Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma]V Scudla, P Petrová, J Minarík, et al.
Vnitrni Lekarstvi|September 1, 1994
[Cytogenetic findings in patients with primary myelodysplastic syndrome and their prognostic significance. (Analysis of results in 65 patients)]K Indrák, M Jarosová, I Sulovská, et al.
Pageof 8